Reports
Spending on medicines in the US increases again in 2015
Growth in spending on medicines in the US increased by US$46.2 billion, or 12.2%, over 2014 levels, reaching US$425 billion in 2015. The increase was fuelled by the number of new medicines launched (43 new active substances were launched in 2015), while the savings from brand-name drugs facing generics competition were relatively low.
Payers in US expect biosimilars to reduce costs
Payers in the US expect the use of biosimilars to be a strategy that can be used to reduce the cost of specialty drugs, according to a report published by biotech giant Amgen.
Prices of brand-name drugs in the US have doubled since 2011
According to Express Scripts, the average price of brand-name drugs in the US has doubled in the past five years and has increased on average by 16.2% since 2015. Express Scripts, the largest pharmacy benefit management organization in the US, based its March 2016 report on prescription use data for members with drug coverage by the organization.
Price/access expected to be major drivers for biosimilars uptake
Payers in the US expect price/access to be the major drivers for biosimilars uptake, according to a report published by biotech giant Amgen.
Pivotal clinical trials for infliximab biosimilars
Biosimilars of Johnson & Johnson’s blockbuster arthritis drug Remicade (infliximab), a chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-α), are currently under development.
Pivotal clinical trials for etanercept biosimilars
Biosimilars of Amgen/Pfizer’s blockbuster arthritis drug Enbrel (etanercept), a fusion protein produced by recombinant DNA, are currently under development.
Biosimilar events from 2013 to 2015
During the period of 2013 to 2015, biosimilars has been increasingly on the agenda around the world. Biosimilars are making steady progress, as can be seen by the increasing number of events, including approvals for biosimilars around the world [1].
Payers in US getting ready for biosimilars
Payers in the US are getting ready for the advent of biosimilars, according to a report published by biotech giant Amgen.
Payers in US view biosimilars as a lower-cost branded option
Payers in the US do not expect the biosimilars market to be like the generics market and they also do not expect the US biosimilars market to be like that in Europe, according to a report published by biotech giant Amgen.
Impact of antidepressant generics in Europe
Use of generic antidepressants may improve adherence and reduce the cost of pharmacotherapy for depression in European countries, according to a report by the Germany-based Institute for Healthcare and Social Research (IGES).
